breast
cancer
common
cancer
lead
caus
cancer
death
women
around
world
heterogen
diseas
divid
sever
subgroup
differ
clinicopatholog
characterist
prognosi
tripleneg
breast
cancer
tnbc
defin
lack
express
estrogen
receptor
er
progesteron
receptor
pr
epiderm
growth
factor
receptor
character
aggress
behavior
onset
young
age
earli
relaps
tnbc
insensit
endocrin
therapi
therefor
chemotherapi
remain
mainstay
treatment
although
clinic
trial
found
tnbc
sensit
platinumbas
chemotherapi
taxaneanthracyclinebas
regimen
still
standard
prefer
regimen
tnbc
patient
adjuv
set
liao
et
al
howev
tnbc
patient
respond
chemotherapi
suggest
tnbc
singl
diseas
identifi
biomark
subdivid
tnbc
patient
distinct
outcom
great
import
aurora
kinas
aurka
aurora
kinas
b
aurkb
member
aurora
kinas
subfamili
conserv
serinethreonin
kinas
aurka
local
duplic
centrosom
begin
phase
shift
bipolar
spindl
microtubul
mitosi
final
move
perinuclear
materi
daughter
cell
end
mitosi
contrast
aurkb
start
earli
local
chromosom
prophas
centromer
prometaphas
metaphas
central
spindl
anaphas
midbodi
cytokinesi
aurka
play
critic
role
centrosom
duplic
matur
aurkb
play
key
role
mitosi
regul
chromosom
align
segreg
cytokinesi
catalyt
protein
chromosom
passeng
complex
cpc
deregul
aurora
kinas
lead
impair
mitot
spindl
checkpoint
caus
abnorm
spindl
assembl
report
singlenucleotid
polymorph
snp
aurka
aurkb
associ
risk
surviv
sever
cancer
includ
breast
cancer
esophag
cancer
till
research
polymorph
aurka
aurkb
prognosi
tnbc
patient
studi
first
demonstr
polymorph
aurka
aurkb
gene
associ
surviv
tnbc
patient
januari
decemb
primari
tnbc
patient
treat
taxanebas
adjuv
chemotherapi
enrol
studi
blood
sampl
collect
patient
patient
follow
juli
collect
data
recurr
death
diseasefre
surviv
df
time
defin
time
date
diagnosi
date
first
locoregion
recurr
first
distant
metastasi
death
caus
whichev
came
first
overal
surviv
os
defin
time
date
diagnosi
date
death
reason
last
followup
formalinfix
paraffinembed
breast
cancer
tissu
sampl
obtain
patient
immunohistochemistri
ihc
perform
antier
antipr
antibodi
use
evalu
er
pr
statu
posit
er
pr
statu
defin
nuclear
stain
accord
guidelin
issu
american
societi
clinic
oncolog
asco
colleg
american
pathologist
cap
determin
statu
ihc
fluoresc
situ
hybrid
fish
perform
tumor
neg
er
pr
defin
tnbc
investig
approv
institut
review
board
chines
academi
medic
scienc
cancer
hospit
conduct
accord
ethic
standard
declar
helsinki
follow
nation
intern
guidelin
written
inform
consent
obtain
patient
genotyp
data
aurka
aurkb
gene
region
encompass
kb
upstream
kb
downstream
flank
sequenc
extract
hapmap
chines
han
popul
hapmap
data
rel
phase
ii
iii
http
wwwhapmaporg
haploview
softwar
http
www
broadinstituteorgmpghaploview
use
identifi
tag
snp
inclus
criteria
snp
known
ethnic
han
chines
peopl
minor
allel
frequenc
maf
final
total
candid
snp
select
genotyp
inform
snp
list
tabl
primer
probe
design
use
massarray
typer
softwar
peripher
blood
sampl
ml
collect
subject
recruit
genom
dna
isol
routin
phenolchloroform
method
dna
sampl
dilut
work
concentr
ngml
genotyp
genotyp
conduct
use
massarray
malditof
system
sequenom
inc
san
diego
ca
usa
method
describ
sequenom
genotyp
protocol
twenti
percent
duplic
sampl
neg
control
without
dna
includ
qualiti
assur
genotyp
concord
duplic
sampl
analyst
carri
genotyp
blind
group
inform
sampl
polymorph
aurka
aurkb
tnbc
estim
use
cox
model
multivari
analysi
adjust
age
vs
histolog
grade
vs
vs
unknown
uk
tumor
size
cm
vs
cm
lymph
node
statu
vs
without
region
lymph
node
metastasi
vascular
invas
vs
without
vascular
invas
perform
subgroup
analysi
polymorph
associ
os
df
patient
multivari
analysi
sinc
patient
gg
genotyp
perform
subgroup
analysi
statist
test
two
side
p
consid
signific
total
patient
enrol
studi
median
age
diagnosi
year
rang
year
os
rate
df
rate
among
total
patient
patient
preand
postmenopaus
stage
respect
seventi
patient
present
grade
grade
tumor
eightyfour
subject
diagnos
stage
ii
iii
respect
relationship
clinicopatholog
characterist
surviv
patient
summar
tabl
patient
grade
tumor
significantli
higher
os
rate
grade
tumor
vs
p
hr
ci
tumor
size
lymph
node
statu
significantli
relat
df
os
signific
associ
observ
age
menopaus
statu
tnbc
surviv
multivari
analysi
tumor
size
p
hr
ci
lymph
node
statu
p
multivari
analysi
aurka
associ
os
sinc
patient
gg
genotyp
explor
relationship
subgroup
shown
tabl
explor
relationship
aurkb
surviv
tnbc
polymorph
aurka
aurkb
report
associ
prognosi
kind
cancer
comprehens
research
investig
associ
polymorph
aurka
aurkb
outcom
tnbc
patient
studi
first
demonstr
aurka
gg
genotyp
carrier
significantli
wors
os
tt
tg
genotyp
carrier
aurkb
c
allel
polymorph
aurka
aurkb
tnbc
associ
wors
df
aurkb
allel
significantli
associ
better
df
aurka
gene
oncogen
locat
chromosom
polymorph
aurka
gene
associ
risk
intrins
subtyp
breast
cancer
studi
ruan
et
al
high
aurka
express
strongli
associ
decreas
surviv
breast
cancer
p
independ
prognost
marker
studi
nadler
et
al
tnbc
patient
aurka
high
express
risk
distant
recurr
peak
first
year
declin
rapidli
thereaft
wherea
patient
aurka
low
express
show
rel
constant
risk
recurr
entir
followup
period
univari
multivari
analysi
show
overexpress
aurka
predict
poor
os
p
progressionfre
surviv
p
tnbc
aurka
report
interact
phosphoryl
sever
import
protein
involv
stress
respons
cell
cycl
checkpoint
dna
damag
overexpress
aurka
led
diminish
transcript
activ
increas
degrad
caus
checkpoint
defect
genet
instabl
ultim
facilit
cancer
develop
progress
aurkb
gene
locat
chromosom
german
popul
synonym
aurkb
g
polymorph
result
increas
famili
breast
cancer
risk
carrier
homozyg
genotyp
ci
p
debat
data
regard
role
aurkb
express
cancer
prognosi
zhang
et
al
found
aurkb
express
correl
prolifer
index
p
express
p
breast
cancer
tissu
higher
express
aurkb
significantli
correl
poor
surviv
case
p
multivari
cox
regress
analysi
demonstr
aurkb
express
independ
prognost
indic
breast
cancer
df
hr
ci
studi
nadler
et
al
polymorph
aurka
aurkb
tnbc
associ
surviv
breast
cancer
patient
none
polymorph
aurkb
studi
report
tnbc
first
found
tc
cc
genotyp
predict
wors
df
subgroup
age
year
postmenopaus
grade
uk
tumor
size
cm
lymph
node
neg
also
predict
shorter
os
subgroup
age
year
grade
ca
aa
genotyp
could
predict
favor
df
premenopaus
grade
lymph
nodeposit
patient
patient
studi
receiv
taxanebas
adjuv
chemotherapi
taxan
microtubul
target
agent
mta
wide
use
drug
adjuv
set
tnbc
patient
cytotox
action
compound
mediat
primarili
bind
monom
lead
microtubul
stabil
thu
block
depolymer
subsequ
trigger
cell
cycl
arrest
phase
consid
role
aurora
kinas
spindl
format
report
extent
deregul
cancer
hypothes
polymorph
aurka
aurkb
might
contribut
taxan
resist
influenc
surviv
cancer
patient
zhang
et
al
demonstr
breast
cancer
patient
receiv
neoadjuv
chemotherapi
contain
sequenti
taxan
anthracyclinebas
regimen
elev
express
aurkb
contribut
chemoresist
p
taxaneresist
breast
cancer
cell
line
express
aurka
significantli
higher
knockdown
aurka
markedli
decreas
express
pgp
also
downregul
pgp
function
resist
breast
cancer
cell
result
indic
aurka
play
crucial
role
paclitaxelresist
breast
cancer
howev
underli
mechan
snp
surviv
tnbc
yet
clear
need
investig
silico
analysi
predict
bind
motif
mesic
et
al
indic
polymorph
site
aurka
aurkb
could
bind
differ
transcript
factor
aurka
g
allel
present
cebpalpha
cebpbeta
transcript
factor
bind
motif
recogn
wherea
region
contain
c
allel
addit
transcript
factor
motif
identifi
case
aurkb
allel
present
tfiii
bind
motif
recogn
contrast
c
allel
present
tfiii
bind
motif
identifi
sinc
express
level
andor
activ
associ
uncheck
cell
prolifer
resist
apoptosi
metastasi
tumor
cell
resist
chemotherapeut
bind
addit
protein
presenc
c
allel
may
alter
level
aurkb
express
influenc
surviv
might
possibl
explan
result
aurkb
allel
significantli
associ
better
df
previou
studi
enrol
differ
subtyp
breast
cancer
patient
regimen
consist
studi
tnbc
patient
enrol
better
explain
correl
polymorph
aurka
aurkb
surviv
limit
studi
first
retrospect
studi
select
bia
might
exist
second
sampl
size
rel
small
prospect
largescal
studi
need
confirm
conclus
final
sinc
explor
mechan
studi
biolog
mechan
warrant
first
time
tnbc
patient
receiv
taxanebas
adjuv
chemotherapi
demonstr
aurka
aurkb
aurkb
associ
surviv
sinc
polymorph
never
report
research
need
verifi
result
